NASDAQ: TWST
Twist Bioscience Corporation
Healthcare · Medical - Diagnostics & Research
Market Cap
$6.84B
52w High
$113.35
52w Low
$23.30
P/E
-49.51
Volume
909.37K
Outstanding Shares
62.27M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 333.51% over the last year. Revenue grew 19.19% over the trailing twelve months. Operating margin moved from -39.3% to -31.91%. Free cash flow declined 35.52% over the trailing twelve months.
What the market seems to be pricing
The stock is trading toward the richer end of its historical P/S range (61st percentile) while business metrics are improving. More of the upside is already embedded in the multiple now.
What would invalidate this read
Operating margin is at -31.91% — continued expansion would be needed to justify the premium. Revenue growth of 19.19% is encouraging, but any deceleration puts the stretched multiple at risk. This read changes if revenue, margins, and cash flow continue to improve faster than expected — in that case the richer multiple could still prove conservative.
Company profile
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA.
Valuation
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
11
Buy
2
Hold
1
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 13, 2026
Q4 FY26 · EPS est -$0.41 · Revenue est $123.5M
View